Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 2 | 77.5% | +20.4% |
| PETERS, ALEC JON | 1 | 69.2% | +53.8% |
| PRONZATI, GINA | 1 | 67.6% | +42.9% |
| KOLKER, DANIEL E | 1 | 49.8% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18190879 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | PRONZATI, GINA | 81d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17843480 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | KOLKER, DANIEL E | 107d overdue |
| 18190879 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | PRONZATI, GINA | 81d overdue |
| 18323342 | USE OF FUSION CONSTRUCTS FOR IL-2 INDEPENDENT T CELL THERAPY | PETERS, ALEC JON | — |
| 18316548 | CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | — |
| 17361621 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1641 | 1 |
| 1633 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18323342 | USE OF FUSION CONSTRUCTS FOR IL-2 INDEPENDENT T CELL THERAPY | PETERS, ALEC JON | 1641 | §102§103§112DP | Non-Final OA | — | Pending | May 24, 2023 |
| 18316548 | CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | May 12, 2023 |
| 18190879 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | PRONZATI, GINA | 1633 | §103§112Other | Non-Final OA | 81d overdue | Pending | Mar 27, 2023 |
| 17843480 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | KOLKER, DANIEL E | 1645 | §103Other | Final Rejection | 107d overdue | Pending | Jun 17, 2022 |
| 17361621 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Jun 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial